Reporting owner · CIK 0001446125

Greenstreet Yvonne

Visual SEC Form 4 history across 1 companies, 46 transactions and 4 filings.

CEOChief Executive OfficerALNYLAM PHARMACEUTICALS, INC.
Open-market mix
Latest filingSep 22, 2026, 08:07 PM
Filings4Form 4 records
Buying$00 purchases
Selling$4.5M41 sales
Net value−$4.5MBuys minus sells
Companies12 securities
Most recentSep 19, 2026grant

Open-market buy performance

90-day forward return on this insider's open-market purchases

90d forward
Forward return is not available yet

We compute this from each buy's stock performance 90 days after the transaction. The price history is still being populated for this insider's their open-market buys, so the average and median will appear here once the daily price refresh has covered the relevant trading days.

Disclosed ownership

How reported shareholdings evolved

Non-derivative shares held after reported transactions—not stock prices or a complete portfolio.

45 observations · Feb 13, 2025 – Sep 19, 2026. Window ends at the latest available report, not today.

Selected observation · Sep 19, 202695,802 shares reported
Inspect transaction
View exact observations and source transactions
Transaction dateShares held afterFiledSource
Feb 13, 202582,739Feb 18, 2025View transaction
Feb 14, 202582,468Feb 18, 2025View transaction
Feb 14, 202582,168Feb 18, 2025View transaction
Feb 14, 202581,967Feb 18, 2025View transaction
Feb 14, 202581,882Feb 18, 2025View transaction
Feb 14, 202581,784Feb 18, 2025View transaction
Feb 14, 202581,737Feb 18, 2025View transaction
Feb 14, 202581,678Feb 18, 2025View transaction
Feb 14, 202581,657Feb 18, 2025View transaction
Feb 14, 202581,619Feb 18, 2025View transaction
Feb 14, 202581,572Feb 18, 2025View transaction
Feb 14, 202581,551Feb 18, 2025View transaction
Feb 14, 202581,526Feb 18, 2025View transaction
Feb 27, 202587,447Mar 3, 2025View transaction
Feb 28, 202587,289Mar 3, 2025View transaction
Feb 28, 202587,166Mar 3, 2025View transaction
Feb 28, 202587,039Mar 3, 2025View transaction
Feb 28, 202586,755Mar 3, 2025View transaction
Feb 28, 202586,294Mar 3, 2025View transaction
Feb 28, 202585,201Mar 3, 2025View transaction
Feb 28, 202584,761Mar 3, 2025View transaction
Feb 28, 202584,547Mar 3, 2025View transaction
Jan 11, 202687,988Jan 14, 2026View transaction
Jan 12, 202687,741Jan 14, 2026View transaction
Jan 12, 202687,472Jan 14, 2026View transaction
Jan 12, 202687,209Jan 14, 2026View transaction
Jan 12, 202686,602Jan 14, 2026View transaction
Jan 12, 202685,824Jan 14, 2026View transaction
Jan 12, 202685,287Jan 14, 2026View transaction
Jan 12, 202684,307Jan 14, 2026View transaction
Jan 12, 202683,683Jan 14, 2026View transaction
Jan 12, 202683,219Jan 14, 2026View transaction
Jan 12, 202682,918Jan 14, 2026View transaction
Jan 12, 202681,659Jan 14, 2026View transaction
Jan 12, 202680,264Jan 14, 2026View transaction
Jan 12, 202679,948Jan 14, 2026View transaction
Jan 12, 202679,687Jan 14, 2026View transaction
Jan 12, 202679,103Jan 14, 2026View transaction
Jan 12, 202678,850Jan 14, 2026View transaction
Jan 12, 202678,732Jan 14, 2026View transaction
Jan 12, 202678,711Jan 14, 2026View transaction
Jan 12, 202678,623Jan 14, 2026View transaction
Jan 12, 202678,505Jan 14, 2026View transaction
Jan 12, 202678,411Jan 14, 2026View transaction
Sep 19, 202695,802Sep 22, 2026View transaction

Securities and direct/indirect ownership contexts are kept separate and never summed. Joint filings may associate the same disclosed row with multiple owners. Unknown values are omitted, not treated as zero. Lines connect observations for readability; they do not establish holdings between filings, cost basis, or current ownership. Amendments and stock splits require reviewing the source.

Monthly open-market activity

Reported purchase and sale transaction counts

Buys Sells
25130-13-2520Feb 2521Jan 26Sep 26

Net value flow

Buys minus sells

Feb 25
−$1M
Jan 26
−$3.5M
Sep 26
$0

Transaction texture

Ownership and ticket size

Average P/S size$109.4K
Median P/S size$68.4K
Direct46
Indirect0
Sep 19, 2026grant

Filing-only signals

Deterministic matches in this insider's history

Cluster Sellingpattern20Derivative Transactionfiling-context1Direct Ownershipfiling-context45Large Holdings Reductionholdings1Large Salesize17Repeat Sellerpattern39

Latest Form 4 facts

Quick context from source filings

Latest transaction

sale at ALNYLAM PHARMACEUTICALS, INC. on Jan 12, 2026 valued at $35,515.

Review SEC filing
Latest buy

No open-market insider purchase is available.

Latest sale

sale at ALNYLAM PHARMACEUTICALS, INC. on Jan 12, 2026 valued at $35,515.

Review SEC filing

Associated companies

Visual map of known reporting history

ALNYLAM PHARMACEUTICALS, INC.ALNY · 46 transactions · latest Sep 22, 2026, 08:07 PM

Latest insider transactions

Form 4 filings from available history. Click any column to sort; click it again to flip the order.

Greenstreet Yvonne transactions
IDTickerInsiderRoleTypeSharesValueCodeFiledTrans date
#161853ALNYGreenstreet Yvonne
CEO
sale123-$2.93MS03/03/202502/28/2025
#161852ALNYGreenstreet Yvonne
CEO
sale158-$3.73MS03/03/202502/28/2025
#161851ALNYGreenstreet Yvonne
CEO
exercise5.92k$0M03/03/202502/27/2025
#130628ALNYGreenstreet Yvonne
CEO
sale25-$662kS02/18/202502/14/2025
#130627ALNYGreenstreet Yvonne
CEO
sale21-$552kS02/18/202502/14/2025
#130626ALNYGreenstreet Yvonne
CEO
sale47-$1.22MS02/18/202502/14/2025
#130625ALNYGreenstreet Yvonne
CEO
sale38-$990kS02/18/202502/14/2025
#130624ALNYGreenstreet Yvonne
CEO
sale21-$545kS02/18/202502/14/2025
#130623ALNYGreenstreet Yvonne
CEO
sale59-$1.52MS02/18/202502/14/2025
#130622ALNYGreenstreet Yvonne
CEO
sale47-$1.21MS02/18/202502/14/2025

Greenstreet Yvonne Insider Activity FAQ

SEC Form 4 context

Who is Greenstreet Yvonne?

Greenstreet Yvonne is a reporting owner in SEC Form 4 filings with reporting owner CIK 0001446125.

Which companies has Greenstreet Yvonne reported transactions for?

ALNYLAM PHARMACEUTICALS, INC.

When was Greenstreet Yvonne's latest insider buy?

No open-market insider purchase is available for this period.

When was Greenstreet Yvonne's latest insider sale?

sale at ALNYLAM PHARMACEUTICALS, INC. on Jan 12, 2026 valued at $35,515.

Where can I see the original SEC filings?

Each transaction row links directly to the source SEC filing so the reported Form 4 details can be reviewed.

Are performance metrics included?

This version does not calculate win rates, forward returns, benchmark-adjusted returns, or high-conviction scores.